Ilaria Scortechini
Ancona, 60126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
Journal: Cancers
Published: January 08, 2026
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.
Journal: Hematological oncology
Published: December 17, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.
Journal: Hematological oncology
Published: October 18, 2025
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
Journal: British journal of haematology
Published: September 07, 2025
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey).
Journal: Leukemia & lymphoma
Published: January 15, 2025
Management of infections for patient treated with ibrutinib in clinical practice.
Journal: Frontiers in oncology
Published: May 06, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Journal: Cancers
Published: January 21, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Journal: American journal of hematology
Published: October 11, 2023
Last Updated: 09/26/2026